

CLAIMS

1. An antibody against an N-terminal peptide of GPC 3.
2. The antibody claimed in Claim 1 wherein the N-terminal peptide of GPC 3 is a secreted form of a peptide found in blood.
3. The antibody claimed in Claim 2 wherein the N-terminal peptide of GPC 3 is a peptide comprising amino acid residues 1-374 of GPC 3 or a peptide comprising amino acid residues 1-358 of GPC 3.
4. The antibody claimed in Claim 3 wherein the N-terminal peptide of GPC 3 is a peptide comprising amino acid residues 1-358 of GPC 3.
5. The antibody claimed in any one of Claims 1-4 which is a monoclonal antibody.
6. The antibody claimed in Claim 1 which is immobilized to an insoluble support.
7. The antibody claimed in Claim 1 which is labeled with a labeling material.

8. An antibody against a C-terminal peptide of GPC 3.
9. The antibody claimed in Claim 8 wherein the C-terminal peptide of GPC 3 is a peptide comprising amino acid residues 359-580 of GPC 3 or a peptide comprising amino acid residues 375-580 of GPC 3.
10. The antibody claimed in Claim 8 wherein the C-terminal peptide of GPC 3 is a peptide comprising amino acid residues 359-580 of GPC 3.
11. The antibody claimed in any one of Claims 8-10 which is a monoclonal antibody.
12. The antibody claimed in any one of Claims 8-10 which is a chimera antibody.
13. The antibody claimed in any one of Claims 8-10 which is a cytotoxic antibody.
14. A cell disrupting agent comprising the antibody claimed in any one of Claims 7-13.
15. The cell disrupting agent claimed in Claim 14 wherein the cell is a cancer cell.

16. An anti-cancer agent comprising the antibody claimed in any one of Claims 8-13.

17. A method for inducing cytotoxicity comprising contacting a cell with the antibody claimed in any one of Claims 8-13.

18. The method claimed in Claim 17 wherein the cell is a cancer cell.